India's NABARD gets government approval to issue deep-discount debt
NEW DELHI, June 13 (Reuters) - India's National Bank for Agriculture and Rural Development (NABARD) has received approval from the federal government to raise up to 195 billion rupees ($2.3 billion) through deep-discount bonds.
NABARD can raise funds via these deep-discount zero-coupon bonds maturing in 10 years, 11 months and 13 days until the end of March 2027, a government document showed on Friday.
($1 = 86.0400 Indian rupees)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
4 hours ago
- Reuters
Japan and US explored possibility of trade deal, Japan trade negotiator says
June 13 (Reuters) - Japan and the U.S. on Friday explored the possibility of a trade agreement, Japan's top tariff negotiator, Ryosei Akazawa, told a briefing, while refraining from commenting how close they are to reaching a deal. "We had a very detailed exchange and explored the possibility of a trade agreement," Akazawa told reporters after he met with U.S. Treasury Secretary Scott Bessent and Commerce Secretary Howard Lutnick separately in Washington in a sixth round of tariff negotiations. It is likely to be the last round before Prime Minister Shigeru Ishiba and U.S. President Donald Trump are to meet in Canada on the sidelines of the Group of Seven leaders' summit, where Japan has been hoping to clinch a deal. Akazawa refrained from commenting on whether the talks have matured enough to reach an agreement, saying a deal is possible only when the leaders of both countries approve everything as a package. He also declined to comment on the chance of Ishiba and Trump reaching an agreement at their upcoming meeting. Japan faces a 24% tariff rate starting in July unless it can negotiate a deal with the U.S. It is also scrambling to find ways to get Washington to exempt its automakers from 25% tariffs on automobiles, Japan's biggest industry.
Reuters
5 hours ago
- Reuters
Higher inflation 'very likely' due to tariffs, says market expert
Melissa Brown, managing director of investment decision research at SimCorp, says "investors are not placing enough emphasis on the inflation environment," and expects higher prices "over the next couple of months."
Daily Mail
6 hours ago
- Daily Mail
AstraZeneca in deal with China firm worth up to £4bn
AstraZeneca has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new treatments for chronic diseases. Britain's largest listed company announced the tie-up with biotech firm CSPC Pharmaceuticals following controversy over its involvement in China. The pharmaceuticals giant will pay CSPC an upfront fee of £81m while a total further payment of up to £3.8billion is available if the drugs reach development and sales-related milestones. AstraZeneca has been ploughing cash into the country, including announcing a £1.8billion research and development hub in the capital Beijing. The firm's former boss in China, Leon Wang, was arrested in October and is still thought to be in detention. More recently, former Tory leader Sir Iain Duncan Smith has accused the pharma giant of 'turning a blind eye to the nature of the Chinese government'. AstraZeneca boss Sir Pascal Soriot said in February: 'We all think about Leon and miss him, but the reality is we are not able to talk to him. We are not allowed.'
